A recently completed clinical trial, named AZURE trial, postulated certain beneficial antitumor activity of bisphosphonates against breast cancer in the adjuvant setting in a subset of postmenopausal women who were negative for MAF transcription factor [53,54]. This evidence concerns the gene MAF and breast carcinoma.